Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

  • STATUS
    Recruiting
  • End date
    Dec 11, 2032
  • participants needed
    50
  • sponsor
    Yale University
Send
Updated on 13 February 2022
See if I qualify
ketamine
depression
bipolar disorder
depressive disorder
scid
depressive symptoms
depressed mood
structured clinical interview
psychotherapy
post-traumatic stress disorder
caffeine

Summary

The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.

Description

The proposed study is the first in humans to assess the necessity of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) stimulation for the emergence of the anti-depressant effects of ketamine. Despite the overall safety and efficacy of ketamine, concerns remain. For example, ketamine is a drug with abuse liability. Similarly, it produces transient cognitive and perceptual changes that are distressing for some patients. Therefore, it is critical to determine which aspects of ketamine's effects on neural systems. To do this, we employ perampanel, an FDA-approved drug that blocks calcium and non-calcium dependent AMPARs. We employ a counter-balanced cross-over design in which ketamine plus perampanel is given on one day, and approximately 21 days later ketamine plus placebo is given. The effects of these drug combinations are assessed via fMRI studies of neural functional connectivity and oxidative metabolism as well as interview and self-report measures on the infusion day and 24 hours later. If perampanel blocks the capacity of ketamine to ameliorate the clinical and neural signatures of major depression, it would suggest that AMPAR stimulation is critical for the anti- depressant effects of ketamine in humans. This would support the further exploration of drugs that selectively enhance the stimulation of AMPARs without blocking N-methyl-D-aspartate receptors (NMDARs), such as AMPAkines and metabotropic glutamate receptor 2 (mGluR2) antagonists as anti-depressants.

Specific hypotheses include:

The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.

Specifically, we will test the following hypotheses:

  1. Perampanel pre-treatment reduces ketamine-related increases in prefrontal functional connectivity and CMRO2 during ketamine infusion in individuals with treatment-resistant depression.
  2. Perampanel pre-treatment reduces ketamine-induced increases in prefrontal CMRO2 and functional connectivity observed at 24 hours in individuals with treatment resistant depression.
  3. Perampanel pre-treatment reduces the positive effect of ketamine on clinical improvement as measured by the Hamilton Depression Inventory (1) at 24 hours in individuals with treatment resistant depression.

Exploratory: Changes in prefrontal functional connectivity and CMRO2 during ketamine infusion and 24 hours post-infusion are correlated with clinical improvement as measured by the Hamilton Depression Inventory in individuals with treatment resistant depression.

As this study is the first, to the investigator's knowledge, to involve using ketamine and perampanel in human subjects, the investigators have included a small out-of-scanner study to test the safety of the ketamine/perampanel combination on 3 healthy subjects. This registration focuses on the main study that will follow the safety evaluation and evaluate the effect of perampanel and ketamine on individuals with treatment resistant depression.

Details
Condition Depressive Disorder, Major, Bipolar Disorder, Post Traumatic Stress Disorder
Treatment Ketamine, Placebo, Perampanel
Clinical Study IdentifierNCT03367533
SponsorYale University
Last Modified on13 February 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Participants between the ages of 18-65
Right-handed as determined by the Edinburgh Handedness Inventory [32]
Current depression as indicated by a score greater than 17 on the full Hamilton Depression Rating Scale
Anti-depressant resistant depressive symptoms, defined by a history of failure of one or more adequate anti-depressant trials
Individuals who have previously received ketamine must have had a positive response. Individuals who report reduced depressive symptoms will be treated as ketamine responders and entered directly into the closed label trial
Participants will meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) Criteria for Major Depressive Disorder, Post-Traumatic Stress Disorder, or Bipolar Disorder as determined by the Structured Clinical Interview for DSM-5 (SCID-5)
All participants given ketamine must be engaged in treatment outside of the research protocol. Those who are not currently in treatment may be referred for treatment
Individuals who are receiving pharmacotherapy for depression must have been receiving the current medication and dose for 4 weeks before randomization. In addition, they should have a plan to continue the current regime of pharmacotherapy for the duration of the trial
Individuals who are receiving psychotherapy must have been in treatment for four weeks and should have a plan to continue the current regime of psychotherapy for the duration of the trial
Willing to refrain from caffeine, drug and alcohol use for one week prior to each MRI session
Females will be included if they are not pregnant or breastfeeding and agree to utilize a medically accepted birth control method (to include oral, injectable, or implant birth control, condom, diaphragm with spermicide, intrauterine device, tubal ligation, abstinence, or partner with vasectomy). Women who are surgically sterile or post-menopausal with cessation of menses for at least one year are not required to use birth control. If a woman should become pregnant during the study, she will be excluded from the trial
Females will receive ketamine during the follicular phase, i.e., in the first week after the start of the menstrual period, if at all possible. If a prospective participant typically has significant menstrual cramps during this entire follicular phase, she will be studied during another part of her cycle. She will be studied during the same part of her cycle for each scan, if possible
Able to read and write English
Have at least a 12th grade education level or equivalent

Exclusion Criteria

A score on the Columbia Suicide Severity Rating Scale [40] in the "intent" or "intent with plan" categories or judged by Dr. Krystal or Dr. Driesen to be at serious risk for suicide
Neurological disorder excluding more than mild head injury as indicated by the presence of any of the following
More than half hour unconsciousness after trauma
More than one hour post-traumatic amnesia
Concussive symptoms such as headache, memory problems, nausea/vomiting, irritability, ringing in the ears, dizziness, balance problems, difficulty concentrating or visual disturbances lasting more than one week after injury
Concussive symptoms as defined above in the first week after injury causing more than one day impairment in typical duties
Four or more concussive events of less severity than the above will also be grounds for exclusion. These events would include post-trauma symptoms such as the individual being dazed, seeing stars, unconscious for less than one half hour, or post-traumatic amnesia of less than an hour
Current therapeutic treatment with ketamine
Current treatment with topiramate, memantine, or barbiturates within two weeks of randomization
Daytime use of benzodiazepines
Treatment with a vagal nerve stimulator, electroconvulsive therapy (ECT), or deep brain stimulation within two weeks of randomization
Current treatment with monoamine oxidase inhibitors within 4 weeks of randomization
Psychosis other than psychotic experiences congruent with depressed mood during a period of depression
Insulin-dependent diabetes or non-insulin dependent diabetes that is poorly controlled
Other major medical disorder unless cleared by a study physician
History of violence unless cleared by Dr. Driesen or Dr. Krystal because of extenuating circumstances. For example, an individual whose violent behavior was always coupled with substance abuse and had obtained stable sobriety with no violent incidents or an individual who had received successful pharmacotherapy for impulse control difficulties may be included
Individual meets criteria for a diagnosis of substance or alcohol use disorder within the three months prior to screening date
A positive on screening urine drug test or, at the study physicians' discretion, on any drug screens given before the scans
A positive screening breathalyzer test or, at the study physicians' discretion, on any breathalyzer test given before the scans
A 12-lead ECG at screening has clinically significant abnormalities as determined by the physician reading the ECG
Abnormality on clinical chemistry or hematology examination at the pre-study medical screening. Subjects with laboratory parameters outside the reference range for this age group will only be included if the study physician considers that such findings will not introduce additional risk factors
History of positive HIV or Hepatitis B
Has received either prescribed or over-the-counter (OTC) centrally active medicine or herbal supplements within the week prior to the MRI scan. Subjects who have taken OTC medication or herbal supplements may still be entered into the study, if, in the opinions of the Principal/Co-Investigator, the medication received will not interfere with the study procedures or compromise safety
Resting blood pressure lower than 85/55 or higher than 140/90, or resting heart rate lower than 45/min or higher than 100/min, unless cleared by study physician. If a subject meets these blood pressure entrance criteria, but is being treated for high blood pressure, the study team will check with the subject's primary care physician or treatment provider to confirm that the subject is stable and normotensive on their current treatment plan
Known sensitivity to ketamine or heparin
History of general intellectual disability
History of claustrophobia
Any clinically significant impairment of color vision or visual acuity after correction available in the scanner
Presence of cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies in vulnerable positions as assessed by a Yale Magnetic Resonance Research Center standard pre-MRI screening questionnaire
Subjects will be advised not to drive or operate heavy machinery for at least 24 hours after completing the infusion
Donation of blood in excess of 500 mL within 56 days prior to dosing or similar loss of blood due to other causes
Potential participants may be eliminated at the discretion of Dr. Krystal, Dr. Driesen, or the study physician
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

ketamine
depression
bipolar disorder
depressive disorder
scid
depressive symptoms
depressed mood
structured clinical interview
psychotherapy
post-traumatic stress disorder
caffeine

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note